RDP Pharma Launches FFG-Supported GreenChem-TechHub Project with TU Wien Partner Towards Next-Generation Drug Discovery
Tulln, Austria / Romanshorn, Switzerland — November 24th, 2025 — RDP Pharma is pleased to announce the launch of GreenChem-TechHub, a 49‑month research initiative funded under the FFG Energy and Environmental Technologies/Circular Economy call. In partnership with the laboratory of Associate Prof. Michael Schnürch at the Technical University of Vienna, the project will pioneer innovative and green solutions for next‑generation medicinal chemistry applications in oncology.
The program will develop and scale new methods, leveraging mechanochemistry, photocatalysis, and asymmetric synthesis towards complex drug candidates.
“ We are absolutely thrilled to announce the launch of our new FFG-funded project and a big thank you to the Austrian Research Promotion Agency (FFG) for their support,“ said Dr. Antony Crisp, Head of Chemistry and RDP Pharma AG.
For media queries and clarifications, please contact:
Nathan Ehrlich
Business Development Manager
RDP Pharma AG
Email: nathan.ehrlich@rdp-pharma.com
Noninvasive Cell Population Profiling of Cervical Biofluids Opens New Path for Companion Diagnostics
Tulln, Austria / Romanshorn, Switzerland — October 15, 2025 — Researchers from Valdospan GmbH, a subsidiary of RDP Pharma AG, in collaboration with the Department of Gynecology and Obstetrics at Karl Landsteiner University of Health Sciences in Tulln have published a groundbreaking study demonstrating the potential of multicolor flow cytometry for noninvasive profiling of cervical cell populations.
The peer-reviewed article, titled “Noninvasive Cell Population Profiling of Normal and Dysplastic Cervical Biofluids by Multicolor Flow Cytometry as a Promising Tool for Companion Diagnostics,” was published in Cancers (2025, 17(20), 3328; https://doi.org/10.3390/cancers17203328).
Authored by Christoph Berger, Wolf Dietrich, Manuela Richter, Florian Kellner, Christian Kühne, and Katharina Strasser, the study highlights how advanced flow cytometry can be applied to routine cervical screening samples to identify cellular and immunological signatures associated with normal and dysplastic conditions.
“Our results demonstrate that cervical biofluids contain valuable information that can be analyzed without invasive biopsies,” said Dr. Katharina Strasser, lead author and Deputy Head of Biology Department at Valdospan GmbH. “This approach opens up exciting possibilities for personalized diagnostics and for guiding targeted therapies in women’s health.”
The research represents a significant step toward developing companion diagnostic tools that support precision medicine in gynecologic oncology. By leveraging noninvasive sampling and high-dimensional flow cytometry, this method could complement existing cytology and HPV testing — providing deeper insights into cellular immune landscapes and disease progression.
This publication underscores RDP Pharma’s commitment to advancing innovative diagnostic platforms that enable early detection, patient stratification, and treatment monitoring through cutting-edge cell analysis technologies.
For media queries and clarifications, please contact:
Nathan Ehrlich
Business Development Manager
RDP Pharma AG
Email: nathan.ehrlich@rdp-pharma.com
RDP Pharma AG to Attend BIO-Europe 2025 in Vienna
Romanshorn, Switzerland – September 26, 2025 – RDP Pharma AG, a pioneering biotech company advancing targeted protein degradation (TPD) where we are ‘Mastering the Unstructured: Rationally Degrading Intrinsically Disordered Region (IDR) Proteins’ and data-driven drug discovery, are pleased to announce our attendance at BIO-Europe 2025, taking place from November 3–5, 2025, in Vienna, Austria.
BIO-Europe is Europe’s largest life science partnering event, bringing together global biopharma executives, innovative biotech companies, investors, and industry experts. The event serves as a premier platform to foster strategic partnerships, explore investment opportunities, and showcase cutting-edge scientific innovation.
RDP Pharma AG’s delegation, including members of the executive and scientific teams, will engage in one-on-one partnering meetings and networking sessions to explore collaborations and share insights into our ongoing work in oncology.
Our vision is a world where fewer diseases remain untreatable. Many diseases are driven by proteins with IDRs (e.g., MYC). Unlike most proteins that have stable, puzzle-piece-like structures, IDR proteins are dynamic, constantly shifting shape to support different cellular functions—much like chameleons. To overcome this challenge, we have developed our proprietary PromptDegrader™ platform to aid in improving quality of life.
Our participation at BIO-Europe 2025 highlights our commitment to expanding our global network and accelerating the translation of breakthrough science into transformative therapies.
We look forward to connecting with our peers and partners in Vienna.
Conference Details:
- Event: BIO-Europe 2025
- Dates: November 3–5, 2025
- Location: Vienna, Austria
- Contact: nathan.ehrlich@rdp-pharma.com
RDP Pharma AG to Attend AITHYRA 2025 in Vienna
Romanshorn, Switzerland – September 5, 2025 – RDP Pharma AG, a pioneering biotech company at the forefront of targeted protein degradation of IDR proteins and data-driven drug discovery, is pleased to announce our attendance at the upcoming AITHYRA Symposium – AI for Life Science, taking place from September 8–10, 2025, in Vienna, Austria.
Dr. Markus Muellner, Chief Technology Officer at RDP Pharma AG, will attend the symposium, which is organized by the Austrian Academy of Sciences and brings together leading researchers and innovators applying artificial intelligence across the life sciences.
AITHYRA 2025 will feature cross-disciplinary sessions addressing key themes such as biomedical data integration, predictive modeling, and the ethical implications of AI in healthcare. RDP Pharma AG’s participation underscores our ongoing commitment to leveraging AI and computational tools to accelerate the development of novel therapeutics in oncology and specifically in the field of TPD.
We look forward to seeing you there.
Conference Details:
- Event: AITHYRA Symposium – AI for Life Science
- Dates: September 8–10, 2025
- Location: The Theater of the Austrian Academy of Sciences, Vienna, Austria
- Contact: info@rdp-pharma.com
RDP Pharma AG to Present at Poster at EFMC-ISMC 2025 in Porto: Advancing the Science of Targeted Protein Degradation in Oncology
Romanshorn, Switzerland – August 27, 2025 – RDP Pharma AG, a pioneering biotech company in the field of targeted protein degradation, is pleased to announce its participation in the upcoming EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC) 2025, taking place from August 31st – September 4th in Porto, Portugal.
Dr. Antony Crisp, Head of Chemistry at RDP Pharma AG, will present the company’s latest research in a poster session titled „Novel Isoquinolone Derivatives As Orally Available HPV16 E7 Targeted Protein Degraders“.
This research highlights the continued development of RDP Pharma’s proprietary PromptDegrader™ platform, with a focus on designing small-molecule degraders that selectively target the oncogenic HPV E7 protein, a driver of multiple HPV-associated cancers. The presentation will showcase how structural insights were leveraged to improve potency, selectivity, and in vitro efficacy of E7 degraders in HPV-positive cancer models.
Conference Details:
- Event: EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC) 2025
- Dates: Aug 31–Sep 4, 2025
- Location: Porto, Portugal
- Presenter: Dr. Antony Crisp, Head of Chemistry
Presentation Title: Novel Isoquinolone Derivatives As Orally Available HPV16 E7 Targeted Protein Degraders
“We are thrilled to present at EFMC-ISMC. We look forward to sharing our PromptDegrader™ platform which is generating potent degraders against challenging and clinically-relevant oncological targets such as E7” – Dr. Antony Crisp
RDP Pharma AG and Experimental Drug Development Centre Launch Strategic Collaboration to Discover and Develop Monovalent Targeted Protein Degraders for Autoimmune Diseases
Romanshorn, Switzerland and Singapore – July 1, 2025 – RDP Pharma AG, a Swiss biotechnology company focused on next-generation protein degradation therapeutics, and the Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development hosted by the Agency for Science, Technology and Research (A*STAR), today announced a strategic research collaboration to jointly discover and develop monovalent targeted protein degraders as potential new therapeutic options for patients with chronic and debilitating autoimmune diseases.
Epidemiological studies have shown that the global incidence and prevalence of autoimmune diseases are rising, with some estimates suggesting annual increases of 19.1% and 12.5%, respectively. The number of incident cases of immune-mediated inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease has grown worldwide. Despite advances in autoimmune disease therapies, there remains a need for treatments with fewer side effects, better or more sustained efficacy, and options for patients who do not respond to existing treatments.
RDP Pharma and EDDC are partnering to address this by combining RDP Pharma’s proprietary PromptDegrader™ platform and expertise in rational protein degrader design with EDDC’s integrated capabilities in target biology, drug discovery, and translational research. The partnership aims to develop an oral therapeutic that selectively degrades a key driver of dysfunctional immune responses in autoimmune diseases.
“This collaboration leverages the unique strengths of both organisations,” said Dr. Markus Muellner, Chief Technology Officer of RDP Pharma AG. “Our platform enables rational design of precision degraders against hard-to-drug targets, and EDDC’s deep expertise in target biology and translational research provides the ideal framework to accelerate development. Together, we aim to unlock new therapeutic avenues in inflammatory diseases where current treatments fall short.”
„This partnership with RDP Pharma exemplifies our commitment to pioneering novel therapeutic approaches,” said Prof Damian O’Connell, Chief Executive Officer of EDDC. “It also builds on our ongoing efforts to strengthen capabilities in monovalent small molecule degrader development. By combining EDDC’s expertise in drug discovery with RDP Pharma’s innovative degrader platform, we aim to accelerate the development of new treatments—creating a transformative impact for patients with chronic inflammatory and autoimmune diseases. It also reinforces our broader mission to collaborate with innovative biotech firms and strengthen Singapore’s drug discovery ecosystem.”
For media queries and clarifications, please contact:
Nathan Ehrlich
Business Development Manager
RDP Pharma AG
Email: nathan.ehrlich@rdp-pharma.com, info@rdp-pharma.com
Aileen Tan
Manager, Corporate Communications
Agency for Science, Technology and Research
Email: aileen_tan@hq.a-star.edu.sg
About RDP Pharma AG
RDP Pharma AG is a Swiss biotech company pioneering rational design of next-generation targeted protein degraders for diseases with high unmet medical need. Its proprietary PromptDegrader™ platform enables development of highly selective, monovalent degrader molecules for challenging targets across oncology, inflammation, and neurodegeneration.
About the Experimental Drug Development Centre (EDDC)
The Experimental Drug Development Centre (EDDC) is Singapore’s national platform for drug discovery and development, formed from the integration of the Experimental Therapeutics Centre (ETC), Drug Discovery and Development (D3), and Experimental Biotherapeutics Centre (EBC) in 2019. EDDC aims to develop therapeutics and diagnostics that save and improve the lives of patients in Singapore, Asia and around the world. Hosted by the Agency for Science, Technology and Research (A*STAR), EDDC works collaboratively with public sector and industry partners to translate the great science arising from Singapore’s biomedical and clinical sciences R&D into innovative healthcare solutions. For more information about EDDC, please visit www.eddc.sg.
PDF is available for download here.
RDP Pharma AG to Present at the AACR Annual Meeting 2025
Romanshorn, Switzerland – April 14, 2025 – RDP Pharma AG is pleased to announce our participation at the AACR Annual Meeting 2025, at the McCormick Place Convention Center, Chicago, IL, USA. At this event, we will present three posters showcasing our drug candidate CP201, which is ready for phase 1 clinical trials in healthy volunteers. For more information on the posters, please see below.
Additionally, we will be there to discuss the latest developments of our unique, innovative Targeted Protein Degradation Platform PROMPT (Protein Modulation Platform Technology).
Our PromptDegrader™ pipeline includes:
- VS035 – First-in-Class, orally available, small molecule-based new chemical entity (NCE) HPV E7 Degrader
- c-Myc – MYC monovalent small molecule degrader-based NCE
- Two additional undisclosed targets
Poster #32
Title: Efficacy and tolerability of an enantiomer of Edelfosine (S-CP201) in pancreatic cancer PDX models as a single agent and in combination with approved drugs in clinical use
Session: Human and PDX Models 1
Date: 27th of April, 2025
Time: 2:00:00 PM – 5:00:00 PM
Location: Poster Section 2 – Board #11
Poster #4346
Title: Improved pharmacokinetic properties of the purified S-enantiomer of the alkylphospholipid Edelfosine compared to the racemic mixture: Potential orally available novel anticancer agent active against pancreatic cancer
Session: Pharmacokinetics and Pharmacodynamics of Cancer Therapeutics
Date: 29th of April, 2025
Time: 9:00:00 AM – 12:00:00 PM
Location: Poster Section 20 – Board #11
Poster #7278
Title: Non-clinical toxicity studies of S-CP201
Session: Novel In Vivo, In Vitro, and In Silico Models
Date: 30th April, 2025
Time: 9:00:00 AM -12:00:00 PM
Location: Poster Section 38 – Board #25
To set up a meeting to discuss our programs including our PROMPT platform please contact us!
Nathan Ehrlich, Business Development Manager – nathan.ehrlich@rdp-pharma.com
Dr. Michael Ahrweiler, Chief Development Officer/Founder – info@rdp-pharma.com
RDP Pharma AG to Present at the Ubiquitin & Friends Symposium 2025: Showcasing Breakthrough Research in HPV E7 Targeted Protein Degradation
Romanshorn, Switzerland – April 14, 2025 – RDP Pharma AG, a leading innovator in the field of targeted protein degradation, is excited to announce its participation in the upcoming 2025 Protein Degradation Symposium, held on May 8th and 9th, 2025. We will present a poster based on our breakthrough work in the development of a unique HPV E7-targeted protein degrader.
The research, titled „Unique HPV E7 Targeted Protein Degrader“, outlines RDP Pharma’s progress in advancing a novel therapeutic strategy for HPV-driven malignancies, including cervical cancer, one of the most prevalent cancers caused by human papillomavirus (HPV). The poster presentation will focus on our innovative work utilizing our proprietary PromptDegrader™ platform to design small-molecule degraders specifically targeting the high-risk HPV E7 oncoprotein.
Conference Details:
- Event: 2025 Protein Degradation Symposium
- Dates: May 8th and 9th, 2025
- Location: Vienna, Austria
- Attendees: Dr. Markus Müllner, CTO; Dr. Florian Kellner, Head of Biology; Dr. Antony Crisp, Head of Chemistry
- Presentation Title: „Unique HPV E7 Targeted Protein Degrader“
- Presenter: Dr. Florian Kellner, Head of Biology
“We are thrilled to be presenting our latest findings at this prestigious event and to showcase our innovative approach to targeting the HPV E7 oncoprotein,” said Dr. Markus Muellner, Chief Technology Officer at RDP Pharma AG.
20.02.2025 – RDP Pharma AG will be Attending the AACR 2025 Annual Meeting
Studies Describing Pre-clinical Development of CP201, a Purified Enantiomer of Edelfosine, Accepted for Presentation at the American Association of Cancer Research (AACR) Annual Meeting in Chicago from April 25th – 30th, 2025
RDP Pharma AG (Switzerland), a private emerging biotechnology company is focused on developing novel therapeutics for cancer and other therapeutic areas. RDP is developing a novel protein degradation platform aimed at hard to drug targets such as c-Myc and viral regulatory proteins. Three AACR abstracts related to our legacy patented compound CP201, an enantiomer of the racemic drug Edelfosine were accepted for the AACR annual meeting. The Edelfosine drug candidate is initially targeted for Glioblastoma Multiforme, a brain cancer.
Abstract details will be disclosed on March 26th.
About RPD Pharma:
RDP Pharma AG was founded in 2019 by a group of industry veterans with decades of experience. Our team is comprised of highly accomplished entrepreneurs, and drug development experts. Our extensive experience ensures that the right questions are asked, the right experiments conducted, and the right clinical studies implemented to advance our programs. Our headquarter is in Romanshorn, Switzerland; and our chemistry and biology research operations are located Tulln, Austria, just outside of Vienna.
About CP201:
CP201 is an orally available enantiomer of the alkyllysophospholipid (ALP) Edelfosine. It is a synthetic etherlipid that is owned by RDP Pharma. Previously, racemic Edelfosine, the parent compound of CP201, was tested in more than 1,300 cancer patients in phase 1 and 2 clinical trials conducted in the 1980s/1990s with encouraging signs of clinical activity in various cancers (e.g. lung cancer, brain cancer) and in patients with multiple sclerosis, whilst showing a favorable toxicity profile (mainly mild to moderate and reversible gastro-intestinal adverse events, e.g. nausea). A large number of patients have been administered edelfosine for over 2 years.
RDP has developed CP201, through extensive preclinical studies and it is ready for phase 1 clinical trials.
For more information please contact:
Dr. Michael Ahrweiler
Founder, Chief Development Officer
Amriswilerstrasse 51
CH-8590 Romanshorn
Switzerland
Tel. +41 71 466 33 68
info@rdp-pharma.com
www.rdp-pharma.com